查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1708018

内分泌检测市场：全球产业分析、规模、份额、成长、趋势和预测（2025-2032）

Endocrine Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计 2025 年全球内分泌检测市场价值将达到 134 亿美元，到 2032 年将达到 232 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.2%。

内分泌检测市场包括使用各种检测技术对荷尔蒙失衡和内分泌腺疾病进行分析和诊断。这包括甲状腺功能、生殖激素、葡萄糖代谢和肾上腺功能的测试。糖尿病、甲状腺疾病和荷尔蒙癌症等内分泌相关疾病的增加推动了对准确、快速和易于获取的检测解决方案的需求。免疫测量和串联式质谱质谱等诊断方法的技术进步彻底改变了内分泌诊断并改善了临床结果。

全球内分泌检测市场受到糖尿病、甲状腺功能亢进和荷尔蒙失衡等内分泌疾病激增的推动，这些疾病由于久坐的生活方式、压力和人口老化而呈上升趋势。人们对早期疾病检测和定期健康监测的认识不断提高，导致已开发地区和发展中地区的诊断检测量显着增加。诊断技术的进步，例如高通量免疫检测、质谱和基于生物感测器的方法的集成，进一步提高了检测的准确性、速度和可负担性。由于患者对便利性和个人化医疗的偏好，居家医疗和照护现场内分泌检测的采用率不断提高，这也是支持市场成长的关键因素。

儘管前景乐观，内分泌检测市场仍面临一定的限制因素。先进的诊断平台和专用设备的高成本往往是中低收入地区的一个障碍。此外，由于实验室间测试准确性的差异和标准化的缺乏，导致诊断结果不一致。新诊断工具的复杂法规和冗长的核准流程也减缓了创新和采用的步伐。此外，许多地区都面临熟练实验室技术人员短缺的问题，影响了检测服务的品质和可靠性。

由于个人化医疗和预测诊断的日益普及，内分泌检测市场充满了成长机会。技术创新不断为下一代测试解决方案打开大门，包括实验室晶片设备、人工智慧整合诊断系统和多重检测，可提供更高的灵敏度和更快的周转时间。新兴经济体，尤其是亚太和拉丁美洲的新兴经济体，由于医疗基础设施发达且患者意识不断提高，拥有尚未开发的潜力。诊断公司和医疗保健提供者之间的策略合作伙伴关係正在推动创新并扩大偏远和服务不足地区进行内分泌检测的机会。此外，预计家用检测套组和远端医疗诊断的兴起将在预测期内推动市场大幅扩张。

本报告研究了全球内分泌检测市场，并按测试、技术、适应症、最终用途、地理位置和公司概况进行细分。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值洞察

第四章全球内分泌检测市场展望

  • 主要亮点
  • 市场规模分析及预测
    • 2019-2024 年历史市场规模分析
    • 2025-2032年目前市场规模分析与预测
  • 全球内分泌检测市场展望（按检测）
    • 2019 年至 2024 年按测试分類的历史市场规模分析
    • 2025 年至 2032 年按测试分類的当前市场规模分析与预测
    • 透过测试进行市场吸引力分析
  • 全球内分泌检测市场技术展望
    • 2019 年至 2024 年按技术分類的历史市场规模分析
    • 2025 年至 2032 年按技术分類的当前市场规模分析与预测
    • 依技术进行市场吸引力分析
  • 全球内分泌检测市场展望（按适应症）
    • 2019 年至 2024 年按适应症分類的历史市场规模分析
    • 目前市场规模分析与预测（按适应症），2025 年至 2032 年
    • 按适应症分析市场吸引力
  • 全球内分泌检测市场前景（依最终用途）
    • 2019 年至 2024 年按最终用途分類的历史市场规模分析
    • 目前市场规模分析与预测（依最终用途），2025 年至 2032 年
    • 依最终用途进行市场吸引力分析

5. 全球内分泌检测市场（按地区）展望

  • 2019 年至 2024 年各地区历史市场规模分析
  • 2025 年至 2032 年各地区目前市场规模分析与预测
    • 北美洲
    • 拉丁美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 中东和非洲
  • 按地区分析市场吸引力

6. 北美内分泌检测市场展望

7. 欧洲内分泌检测市场展望

第八章东亚内分泌检测市场展望

9. 南亚和大洋洲内分泌检测市场展望

10. 拉丁美洲内分泌检测市场展望

第 11 章中东和非洲内分泌检测市场展望

第十二章竞争格局

  • 2025年市场占有率分析
  • 市场结构
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • Abbott Laboratories, Inc.
    • AB Sciex Pte. Ltd.
    • Agilent Technologies, Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings（LabCorp）
    • Quest Diagnostics, Inc.
    • Thermo Fisher Scientific, Inc.
    • MP Biomedicals
    • Ortho-Clinical Diagnostics（QuidelOrtho Corporation）
    • Siemens Healthineers AG
    • Sysmex Corporation
    • 其他的

第十三章 附录

简介目录
Product Code: PMRREP35201

Persistence Market Research has recently released a comprehensive report on the global Endocrine Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Endocrine Testing Market Size (2025E): US$ 13.4 Bn
  • Projected Market Value (2032F): US$ 23.2 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Endocrine Testing Market - Report Scope:

The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.

Market Growth Drivers:

The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies-such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods-are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.

Market Restraints:

Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.

Market Opportunities:

The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions-such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays-that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.

Key Questions Answered in the Report:

  • What are the primary factors driving the global endocrine testing market's growth?
  • Which test types and technologies are gaining the most traction among healthcare providers?
  • How are innovations in diagnostic tools impacting endocrine disease management?
  • Who are the major players in the endocrine testing market, and what strategies are they employing?
  • What are the regional trends and long-term projections for the endocrine testing market?

Competitive Intelligence and Business Strategy:

Leading players in the global endocrine testing market-including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche-are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.

Companies Covered in This Report:

  • Abbott Laboratories, Inc.
  • AB Sciex Pte. Ltd.
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.

Market Segmentation:

By Test:

  • Testosterone Test
  • Estradiol Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Luteinizing Hormone (LH) Test
  • Progesterone Test
  • Human Chorionic Gonadotropin (hCG) Hormone Test
  • Insulin Test
  • Others

By Technology:

  • Tandem Mass Spectrometry
  • Immunoassay
  • Monoclonal & Polyclonal Antibody Technologies
  • Clinical Chemistry Analyzers
  • Others

By Disease Indication:

  • Diabetes
  • Hyperthyroidism
  • Menopause
  • Osteoporosis
  • Cancer
  • Others

By End Use:

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Care Centers
  • Home-based Tests
  • Specialty Centers
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Endocrine Testing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Test Adoption / Usage Analysis
  • 3.3. Government Initiatives & Funding in Endocrine Testing
  • 3.4. Key Market Players
  • 3.5. Regulatory Landscape
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis
  • 3.8. Consumer Behavior Analysis

4. Global Endocrine Testing Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Endocrine Testing Market Outlook: Test
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Test, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
      • 4.3.2.1. Testosterone Test
      • 4.3.2.2. Estradiol Test
      • 4.3.2.3. Thyroid Stimulating Hormone (TSH) Test
      • 4.3.2.4. Prolactin Test
      • 4.3.2.5. Luteinizing Hormone (LH) Test
      • 4.3.2.6. Progesterone Test
      • 4.3.2.7. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 4.3.2.8. Insulin Test
      • 4.3.2.9. Others
    • 4.3.3. Market Attractiveness Analysis: Test
  • 4.4. Global Endocrine Testing Market Outlook: Technology
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.2.1. Tandem Mass Spectrometry
      • 4.4.2.2. Monoclonal & Polyclonal Antibody Technologies
      • 4.4.2.3. Clinical Chemistry
      • 4.4.2.4. Immunoassay
      • 4.4.2.5. Others
    • 4.4.3. Market Attractiveness Analysis: Technology
  • 4.5. Global Endocrine Testing Market Outlook: Disease Indication
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
      • 4.5.2.1. Diabetes
      • 4.5.2.2. Hyperthyroidism
      • 4.5.2.3. Menopause
      • 4.5.2.4. Osteoporosis
      • 4.5.2.5. Cancer
      • 4.5.2.6. Others
    • 4.5.3. Market Attractiveness Analysis: Disease Indication
  • 4.6. Global Endocrine Testing Market Outlook: End-use
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
      • 4.6.2.1. Hospitals
      • 4.6.2.2. Diagnotics Laboratories
      • 4.6.2.3. Ambulatory Care Centers
      • 4.6.2.4. Home-based Tests
      • 4.6.2.5. Speciality Centers
      • 4.6.2.6. Others
    • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Endocrine Testing Market Outlook Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Endocrine Testing Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Test
    • 6.1.3. By Technology
    • 6.1.4. By Disease Indication
    • 6.1.5. By End-Use
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 6.3.1. Testosterone Test
    • 6.3.2. Estradiol Test
    • 6.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 6.3.4. Prolactin Test
    • 6.3.5. Luteinizing Hormone (LH) Test
    • 6.3.6. Progesterone Test
    • 6.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 6.3.8. Insulin Test
    • 6.3.9. Others
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.4.1. Tandem Mass Spectrometry
    • 6.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 6.4.3. Clinical Chemistry
    • 6.4.4. Immunoassay
    • 6.4.5. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 6.5.1. Diabetes
    • 6.5.2. Hyperthyroidism
    • 6.5.3. Menopause
    • 6.5.4. Osteoporosis
    • 6.5.5. Cancer
    • 6.5.6. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Diagnotics Laboratories
    • 6.6.3. Ambulatory Care Centers
    • 6.6.4. Home-based Tests
    • 6.6.5. Speciality Centers
    • 6.6.6. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Endocrine Testing Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Test
    • 7.1.3. By Technology
    • 7.1.4. By Disease Indication
    • 7.1.5. By End-use
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 7.3.1. Testosterone Test
    • 7.3.2. Estradiol Test
    • 7.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 7.3.4. Prolactin Test
    • 7.3.5. Luteinizing Hormone (LH) Test
    • 7.3.6. Progesterone Test
    • 7.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 7.3.8. Insulin Test
    • 7.3.9. Others
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.4.1. Tandem Mass Spectrometry
    • 7.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 7.4.3. Clinical Chemistry
    • 7.4.4. Immunoassay
    • 7.4.5. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 7.5.1. Diabetes
    • 7.5.2. Hyperthyroidism
    • 7.5.3. Menopause
    • 7.5.4. Osteoporosis
    • 7.5.5. Cancer
    • 7.5.6. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Diagnotics Laboratories
    • 7.6.3. Ambulatory Care Centers
    • 7.6.4. Home-based Tests
    • 7.6.5. Speciality Centers
    • 7.6.6. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Endocrine Testing Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Test
    • 8.1.3. By Disease Indication
    • 8.1.4. By End-Use
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 8.3.1. Testosterone Test
    • 8.3.2. Estradiol Test
    • 8.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 8.3.4. Prolactin Test
    • 8.3.5. Luteinizing Hormone (LH) Test
    • 8.3.6. Progesterone Test
    • 8.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 8.3.8. Insulin Test
    • 8.3.9. Others
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.4.1. Tandem Mass Spectrometry
    • 8.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 8.4.3. Clinical Chemistry
    • 8.4.4. Immunoassay
    • 8.4.5. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 8.5.1. Diabetes
    • 8.5.2. Hyperthyroidism
    • 8.5.3. Menopause
    • 8.5.4. Osteoporosis
    • 8.5.5. Cancer
    • 8.5.6. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Diagnotics Laboratories
    • 8.6.3. Ambulatory Care Centers
    • 8.6.4. Home-based Tests
    • 8.6.5. Speciality Centers
    • 8.6.6. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Endocrine Testing Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Test
    • 9.1.3. By Technology
    • 9.1.4. By Disease Indication
    • 9.1.5. By End-Use
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 9.3.1. Testosterone Test
    • 9.3.2. Estradiol Test
    • 9.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 9.3.4. Prolactin Test
    • 9.3.5. Luteinizing Hormone (LH) Test
    • 9.3.6. Progesterone Test
    • 9.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 9.3.8. Insulin Test
    • 9.3.9. Others
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.4.1. Tandem Mass Spectrometry
    • 9.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 9.4.3. Clinical Chemistry
    • 9.4.4. Immunoassay
    • 9.4.5. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 9.5.1. Diabetes
    • 9.5.2. Hyperthyroidism
    • 9.5.3. Menopause
    • 9.5.4. Osteoporosis
    • 9.5.5. Cancer
    • 9.5.6. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Diagnotics Laboratories
    • 9.6.3. Ambulatory Care Centers
    • 9.6.4. Home-based Tests
    • 9.6.5. Speciality Centers
    • 9.6.6. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Endocrine Testing Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Test
    • 10.1.3. BY Technology
    • 10.1.4. By Disease Indication
    • 10.1.5. By End-Use
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 10.3.1. Testosterone Test
    • 10.3.2. Estradiol Test
    • 10.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 10.3.4. Prolactin Test
    • 10.3.5. Luteinizing Hormone (LH) Test
    • 10.3.6. Progesterone Test
    • 10.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 10.3.8. Insulin Test
    • 10.3.9. Others
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.4.1. Tandem Mass Spectrometry
    • 10.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 10.4.3. Clinical Chemistry
    • 10.4.4. Immunoassay
    • 10.4.5. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 10.5.1. Diabetes
    • 10.5.2. Hyperthyroidism
    • 10.5.3. Menopause
    • 10.5.4. Osteoporosis
    • 10.5.5. Cancer
    • 10.5.6. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Diagnotics Laboratories
    • 10.6.3. Ambulatory Care Centers
    • 10.6.4. Home-based Tests
    • 10.6.5. Speciality Centers
    • 10.6.6. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Endocrine Testing Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Test
    • 11.1.3. By Technology
    • 11.1.4. By Disease Indication
    • 11.1.5. By End-Use
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 11.3.1. Testosterone Test
    • 11.3.2. Estradiol Test
    • 11.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 11.3.4. Prolactin Test
    • 11.3.5. Luteinizing Hormone (LH) Test
    • 11.3.6. Progesterone Test
    • 11.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 11.3.8. Insulin Test
    • 11.3.9. Others
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.4.1. Tandem Mass Spectrometry
    • 11.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 11.4.3. Clinical Chemistry
    • 11.4.4. Immunoassay
    • 11.4.5. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 11.5.1. Diabetes
    • 11.5.2. Hyperthyroidism
    • 11.5.3. Menopause
    • 11.5.4. Osteoporosis
    • 11.5.5. Cancer
    • 11.5.6. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Diagnotics Laboratories
    • 11.6.3. Ambulatory Care Centers
    • 11.6.4. Home-based Tests
    • 11.6.5. Speciality Centers
    • 11.6.6. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott Laboratories, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. AB Sciex Pte. Ltd.
    • 12.3.3. Agilent Technologies, Inc.
    • 12.3.4. bioMerieux SA
    • 12.3.5. Bio-Rad Laboratories Inc.
    • 12.3.6. DiaSorin S.p.A.
    • 12.3.7. F. Hoffmann-La Roche Ltd.
    • 12.3.8. Laboratory Corporation of America Holdings (LabCorp)
    • 12.3.9. Quest Diagnostics, Inc.
    • 12.3.10. Thermo Fisher Scientific, Inc.
    • 12.3.11. MP Biomedicals
    • 12.3.12. Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
    • 12.3.13. Siemens Healthineers AG
    • 12.3.14. Sysmex Corporation
    • 12.3.15. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations